8-K
filed May 7, 2026, 7:59 PM ET
ticker RAPP
CIK 0002012593
earnings
confidence high
sentiment positive
materiality 0.75
Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026
Rapport Therapeutics, Inc.
2026-Q1 EPS reported
-$0.42
revenue$20,000,000
- Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.
- Cash $476.8M at March 31, 2026; runway into 2H 2029.
- RAP-219 Phase 3 for focal onset seizures on track to begin Q2 2026; follow-up data showed 90% median seizure reduction weeks 9-12.
- Bipolar mania Phase 2 topline results now expected Q4 2026 (ahead of prior 1H 2027 guidance).
- R&D expense $32.7M (up from $19.6M); G&A $11.5M ($7.5M); Tenacia collaboration signed March 2026.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-210324
- form_type
- 8-K
- ticker
- RAPP
- cik
- 0002012593
- company_name
- Rapport Therapeutics, Inc.
- filed_at
- 2026-05-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.381880+00:00
- generated_at
- 2026-05-14T22:05:44.703771+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-210324
- json_url
- https://secwatch.observer/filing/0001193125-26-210324.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-210324.md
- text_url
- https://secwatch.observer/filing/0001193125-26-210324.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/0001193125-26-210324-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-20260507.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
HIVE
HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M
HIVE Digital Technologies Ltd.
June 2, 2026, 6:23 AM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated
Filing page
SEC filing
DCI
Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)
DONALDSON Co INC
June 1, 2026, 5:41 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
press release is furnished herewith as Exhibit 99.1.
--- EX-99.1 (EX-99.1) ---
Donaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,
Filing page
SEC filing
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted
Filing page
SEC filing
CRDO
Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs
Credo Technology Group Holding Ltd
June 1, 2026, 4:08 PM ET
earnings
Items 2.02, 5.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
Exchange Act, unless such subsequent filing specifically references this Form 8-K.
--- EX-99.1 (EX-99.1) ---
To Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue
Filing page
SEC filing
DXYN
Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%
DIXIE GROUP INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000
Filing page
SEC filing
SNDA
Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition
SONIDA SENIOR LIVING, INC.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 8.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.
Filing page
SEC filing
URG
Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced
UR-ENERGY INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.
Comparable filing
a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.